Biotech discovers solid tumor-killing immune cells in patients' blood.

Chicago-based CTRL Therapeutics has raised $10m to develop a new autologous cell therapy that aims to expand beyond the current scope of cancers treated by existing cell therapies and introduce a less complex process for patients and manufacturers. The company is building on another next-generation cell therapy method known as tumor infiltrating lymphocyte, or TIL, therapy, which requires surgically removing cells from the patient’s tumor.